Genetic Signatures Limited (ASX: GSS)

Market Cap	154.41M
Revenue (ttm)	13.77M
Net Income (ttm)	-17.86M
Shares Out	227.08M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,270
Open	0.700
Previous Close	0.675
Day's Range	0.675 - 0.700
52-Week Range	0.380 - 0.850
Beta	0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 20, 2024

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: GSS

Financial Performance

In 2024, Genetic Signatures's revenue was 13.77 million, a decrease of -36.00% compared to the previous year's 21.51 million. Losses were -17.86 million, 27.1% more than in 2023.